Olema Oncology
Developing therapies that offer the potential to improve outcomes for women living with cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $250m | Private Placement VC | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation targeted therapies for women's cancers.
Its lead product candidate, palazestrant (OP-1250), is a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being developed for the treatment of ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
The company is also developing a KAT6 inhibitor program, which is in the preclinical stage. Olema is conducting a Phase 3 clinical trial of palazestrant in combination with CDK4/6 inhibitors in patients with advanced or metastatic ER+/HER2- breast cancer.
Olema has a clinical trial collaboration and supply agreement with Novartis to evaluate palazestrant in combination with Novartis' CDK4/6 inhibitor ribociclib and mTOR inhibitor everolimus in patients with ER+/HER2- advanced or metastatic breast cancer.
Keywords: biopharmaceutical, oncology, women's cancer, breast cancer, targeted therapies, palazestrant, estrogen receptor, KAT6 inhibitor, clinical trials, drug development